Article
Pharmacogenetically based dosing of thiopurines in childhood acute lymphoblastic leukemia: influence on cure rates and risk of second cancer.
Pediatric blood & cancer - 1 May 2014
Levinsen Mette, Rotevatn Elisabeth Ørskov, Rosthøj Susanne, Nersting Jacob, Abrahamsson Jonas, Appell Malin Lindqvist, Bergan Stein, Bechensteen Anne-Grete, Harila-Saari Arja, Heyman Mats, Jonsson Olafur Gisli, Maxild Jakob Bernhard Cohn, Niemi Mikko, Söderhäll Stefan, Schmiegelow Kjeld
Abstract excerpt
BACKGROUND: Previous studies have indicated that patients with thiopurine methyltransferase (TPMT) low activity (TPMT(LA)) have reduced risk of relapse but increased risk of second malignant neoplasm (SMN) compared to patients with TPMT wild-type (TPMT(WT)) when treated with 6 MP maintenance therapy starting doses of 75 mg/m(2)/day. To reduce SMN risk, 6MP starting doses were reduced to 50 mg/m(2)/day for...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.